| Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. | |
| | |
MedLine Citation:
|
PMID: 3284975 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious than TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have achieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered. |
| | |
Authors:
|
J N Ingle; D I Twito; D J Schaid; S A Cullinan; J E Krook; J A Mailliard; R F Marschke; H J Long; J G Gerstner; H E Windschitl |
Related Documents
:
|
3660475 - Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and c... 16410685 - Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced... 11181655 - Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breas... 9556785 - Phase ii and iii clinical trials of toremifene for metastatic breast cancer. 22236865 - Higher expression of epha2 and ephrin-a1 is related to favorable clinicopathological fe... 8041525 - Appraisal of the modalities used to evaluate an initial abnormal papanicolaou smear. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 6 ISSN: 0732-183X ISO Abbreviation: J. Clin. Oncol. Publication Date: 1988 May |
Date Detail:
|
Created Date: 1988-06-10 Completed Date: 1988-06-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 825-31 Citation Subset: IM |
Affiliation:
|
Division of Medical Oncology, Mayo Clinic, Rochester, MN. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Breast Neoplasms / drug therapy*, mortality Clinical Trials as Topic Female Fluoxymesterone / administration & dosage*, adverse effects Humans Menopause Middle Aged Neoplasm Metastasis Random Allocation Tamoxifen / administration & dosage, adverse effects, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
CA-25224/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
10540-29-1/Tamoxifen; 76-43-7/Fluoxymesterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and ...
Next Document: N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer.